Amyloid-beta is deeply involved in Alzheimer’s disease, but calling it “the cause” oversimplifies what’s actually happening. For over 30 years, the amyloid cascade hypothesis has dominated Alzheimer’s research, proposing that a buildup of amyloid-beta protein fragments in the brain sets off a chain reaction leading to memory loss and dementia. The evidence supporting this idea is substantial, yet it’s become clear that amyloid alone doesn’t tell the whole story.
The Amyloid Cascade Hypothesis
In 1992, researchers John Hardy and Gerald Higgins proposed that amyloid-beta deposits in the brain are the central, triggering event in Alzheimer’s disease, and that everything else, including tangled proteins inside neurons, cell death, and cognitive decline, follows as a direct consequence. This idea, called the amyloid cascade hypothesis, has shaped the direction of Alzheimer’s research ever since.
Here’s the basic biology. Your brain cells contain a large protein called APP that sits in cell membranes. Enzymes cut APP into smaller pieces, and some of those pieces are amyloid-beta fragments. The most common fragments are 40 and 42 amino acids long. The 42-amino-acid version is stickier and more prone to clumping together. In people with certain inherited mutations that cause aggressive, early-onset Alzheimer’s, these enzymes cut APP in ways that produce more of the longer, clump-prone fragments. That genetic link is one of the strongest arguments that amyloid plays a causal role.
What those clumps do to brain cells has been studied extensively. Amyloid-beta disrupts the way neurons send and receive signals, interferes with the cellular machinery that forms memories, and eventually kills brain cells. Importantly, researchers have shifted their focus from the large, visible plaques that show up on brain scans to smaller, soluble clusters of amyloid-beta called oligomers. These oligomers appear to be far more toxic than the plaques themselves, and their levels correlate more closely with symptom severity.
Why Amyloid Alone Isn’t Enough
If amyloid-beta were the sole cause of Alzheimer’s, you’d expect everyone with significant amyloid buildup to develop dementia. They don’t. A large meta-analysis published in JAMA found that among people with completely normal cognition, amyloid positivity rises steadily with age: about 10% of 50-year-olds, 28% of 75-year-olds, and 44% of 90-year-olds have measurable amyloid deposits in their brains without any signs of cognitive problems. That’s a remarkable number of people walking around with the supposed “cause” of Alzheimer’s and experiencing no symptoms at all.
The gap between amyloid buildup and symptom onset is also strikingly long. Brain imaging studies suggest amyloid deposits appear 20 to 30 years before a person shows clinical signs of dementia. This means amyloid accumulation may be necessary to start the disease process, but something else determines whether and when that process leads to actual cognitive decline.
The Tau Connection
One of the most important “something elses” is tau, another protein that goes wrong in Alzheimer’s. Tau normally helps stabilize the internal scaffolding of neurons. In Alzheimer’s, it becomes excessively modified with chemical tags (a process called hyperphosphorylation), causing it to detach from the scaffolding and clump into tangles inside neurons. These tangles are closely tied to cell death and track much more tightly with the progression of symptoms than amyloid plaques do.
Amyloid-beta appears to accelerate this tau dysfunction. It activates specific enzymes inside neurons that add those chemical tags to tau at multiple sites. One enzyme primes tau at certain locations, changing its shape so that a second enzyme can rapidly tag it at additional sites. The result is a snowball effect: amyloid triggers tau problems, and those tau problems drive the neurodegeneration that actually produces memory loss and cognitive decline. In this view, amyloid is less a direct killer and more a match that lights a longer fuse.
Inflammation and the Brain’s Immune Cells
The brain has its own immune cells called microglia. Under normal conditions, they patrol the brain, clear debris, and support healthy neuron function. When amyloid-beta starts accumulating, microglia initially respond helpfully by engulfing and breaking down the amyloid fragments. But prolonged exposure to amyloid shifts microglia into a chronically activated, inflammatory state. In this state, they lose their ability to clear amyloid effectively and instead release toxic molecules, including inflammatory signals, reactive oxygen species, and nitric oxide.
This creates a vicious cycle. Chronic inflammation damages the blood-brain barrier, allowing other immune cells to enter the brain and activate even more microglia. The inflammatory signals themselves promote further amyloid production and accelerate tau pathology. Mutations in genes related to microglial function are now recognized as significant risk factors for Alzheimer’s, suggesting that the brain’s inflammatory response isn’t just a bystander but an active driver of the disease.
The APOE4 Gene and Amyloid Buildup
The strongest genetic risk factor for the common, late-onset form of Alzheimer’s is a variant of the APOE gene called APOE4. About 25% of people carry at least one copy. By age 90, more than 80% of cognitively normal APOE4 carriers already have detectable amyloid in their brains, compared to about 40% of non-carriers.
APOE4 affects amyloid levels from both directions. On the production side, it increases the activity of the enzyme that starts the process of cutting APP into amyloid-beta fragments. It also raises cholesterol levels in neuron membranes, which helps position APP where those cutting enzymes can reach it more easily. On the clearance side, APOE4 suppresses the enzymes that break down amyloid-beta in the brain, and APOE4 carriers show significantly lower levels of these cleanup enzymes. The protein produced by APOE4 is also more compact and unstable than other versions, which impairs its ability to help transport and clear amyloid degradation products. The net effect is more amyloid being produced and less being removed.
What Anti-Amyloid Drugs Have Revealed
If the amyloid hypothesis is correct, removing amyloid from the brain should slow or stop the disease. Dozens of clinical trials have tested this idea, and the results have been humbling. Many drugs successfully cleared amyloid from the brain but produced no meaningful cognitive benefit.
The most likely explanation is timing. By the time a person has symptoms of Alzheimer’s, the downstream cascade of tau tangles, inflammation, and neuron death may already be self-sustaining. Removing the original trigger at that point is like turning off the stove after the house is on fire. Trials also may not have run long enough, and biological differences between participants (including co-existing brain pathologies) likely diluted the results. There’s even a provocative counterargument: some researchers have proposed that amyloid production is actually a protective response to toxic insults in the brain, meaning removing it could be counterproductive in some contexts.
More recent drugs have shown modest but real effects. Lecanemab, tested in an 18-month trial of people with early-stage Alzheimer’s, reduced brain amyloid by about 59 centiloids (a standardized measure of plaque burden) and slowed cognitive decline by 27% compared to placebo. The benefit was statistically significant but clinically small, enough to be measurable on rating scales but not always noticeable in daily life. This pattern, clearing amyloid helps a little but not dramatically, fits a picture where amyloid is one important piece of a larger puzzle.
How Sleep Clears Amyloid From the Brain
Your brain has a waste-clearance system, sometimes called the glymphatic system, that flushes out metabolic byproducts including amyloid-beta. This system is most active during sleep, particularly during deep, slow-wave sleep stages characterized by high delta-wave activity on brain recordings. During sleep, the resistance of brain tissue drops, allowing cerebrospinal fluid to flow more freely through the spaces between cells and carry amyloid-beta and tau out of the brain and into the bloodstream for disposal.
This is one reason chronic poor sleep is considered a risk factor for Alzheimer’s. Less deep sleep means less efficient overnight clearance of amyloid, which over years could contribute to the gradual buildup that precedes disease. It also helps explain why amyloid accumulation is such a slow process, taking decades before it reaches levels that trigger symptoms.
How Alzheimer’s Is Now Defined
The relationship between amyloid and Alzheimer’s has become so central that the disease is now defined biologically rather than by symptoms alone. Under criteria established by the National Institute on Aging and the Alzheimer’s Association in 2024, Alzheimer’s can be diagnosed based on a single positive amyloid biomarker, whether from a PET brain scan, a spinal fluid test, or (as of 2025) a blood test measuring specific protein ratios. This means a person can be diagnosed with Alzheimer’s disease before they have any cognitive symptoms, purely based on the presence of amyloid pathology.
The practical implication is significant. Amyloid is treated as a defining feature of the disease, not merely a risk factor. Whether this biological definition fully captures what “causes” Alzheimer’s remains an open question, but it reflects the current scientific consensus that amyloid pathology is where the disease begins, even if it isn’t where the damage ends.